Dynamic right ventricular-pulmonary arterial uncoupling during maximum incremental exercise in exercise pulmonary hypertension and pulmonary arterial hypertension.

Abstract:

:Despite recent advances, the prognosis of pulmonary hypertension (PH) remains poor. While the initial insult in PH implicates the pulmonary vasculature, the functional state, exercise capacity, and survival of such patients are closely linked to right ventricular (RV) function. In the current study, we sought to investigate the effects of maximum incremental exercise on the matching of RV contractility and afterload (i.e. right ventricular-pulmonary arterial [RV-PA] coupling) in patients with exercise PH (ePH) and pulmonary arterial hypertension (PAH). End-systolic elastance (Ees), pulmonary arterial elastance (Ea), and RV-PA coupling (Ees/Ea) were determined using single-beat pressure-volume loop analysis in 40 patients that underwent maximum invasive cardiopulmonary exercise testing. Eleven patients had ePH, nine had PAH, and 20 were age-matched controls. During exercise, the impaired exertional contractile reserve in PAH was associated with blunted stroke volume index (SVI) augmentation and reduced peak oxygen consumption (peak VO2 %predicted). Compared to PAH, ePH demonstrated increased RV contractility in response to increasing RV afterload during exercise; however, this was insufficient and resulted in reduced peak RV-PA coupling. The dynamic RV-PA uncoupling in ePH was associated with similarly blunted SVI augmentation and peak VO2 as PAH. In conclusion, dynamic rest-to-peak exercise RV-PA uncoupling during maximum exercise blunts SV increase and reduces exercise capacity in exercise PH and PAH. In ePH, the insufficient increase in RV contractility to compensate for increasing RV afterload during maximum exercise leads to deterioration of RV-PA coupling. These data provide evidence that even in the early stages of PH, RV function is compromised.

journal_name

Pulm Circ

journal_title

Pulmonary circulation

authors

Singh I,Rahaghi FN,Naeije R,Oliveira RKF,Vanderpool RR,Waxman AB,Systrom DM

doi

10.1177/2045894019862435

subject

Has Abstract

pub_date

2019-07-01 00:00:00

pages

2045894019862435

issue

3

eissn

2045-8932

issn

2045-8940

journal_volume

9

pub_type

杂志文章
  • Idiopathic hypereosinophilic syndrome with pulmonary hypertension.

    abstract::Hypereosinophilic syndrome is a myeloproliferative disorder characterized by persistent eosinophilia with involvement of multiple organs. The occurrence of severe pulmonary hypertension (PH) in the setting of hypereosinophilic syndrome is very uncommon. A 43-year-old man with documented idiopathic hypereosinophlic syn...

    journal_title:Pulmonary circulation

    pub_type:

    doi:10.1177/2045894018793999

    authors: Zhang L,Peng X,Adhikari BK,Li B,Liu Q,Mikeladze J,Zhang W

    更新日期:2019-01-01 00:00:00

  • Erratum.

    abstract::[This corrects the article DOI: 10.1086/688060.]. ...

    journal_title:Pulmonary circulation

    pub_type: 已发布勘误

    doi:10.1086/689215

    authors:

    更新日期:2016-12-01 00:00:00

  • Rescue balloon pulmonary angioplasty in a rapidly deteriorating chronic thromboembolic pulmonary hypertension patient with liver failure and refractory infection.

    abstract::Pulmonary endarterectomy (PEA) is the standard therapy for chronic thromboembolic pulmonary hypertension (CTEPH). Balloon pulmonary angioplasty (BPA) is an alternative therapy for such patients. Here we report the case of a 60-year-old woman who presented with severe CTEPH resulting in low cardiac output and liver fai...

    journal_title:Pulmonary circulation

    pub_type:

    doi:10.1086/675643

    authors: Tsuji A,Ogo T,Demachi J,Ono Y,Sanda Y,Morita Y,Fukuda T,Nakanishi N

    更新日期:2014-03-01 00:00:00

  • Incidence and risk factors of chronic thromboembolic pulmonary hypertension following venous thromboembolism, a population-based cohort study in England.

    abstract::Chronic thromboembolic pulmonary hypertension (CTEPH) is a complication of unresolved organised pulmonary emboli/thrombi obstructing the major pulmonary arteries. The aim of this study was to estimate the incidence and risk factors of CTEPH in a cohort with first venous thromboembolism (VTE). This was a population-bas...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1177/2045894018791358

    authors: Martinez C,Wallenhorst C,Teal S,Cohen AT,Peacock AJ

    更新日期:2018-07-01 00:00:00

  • Pulmonary arterial hypertension: Specialists' knowledge, practices, and attitudes of genetic counseling and genetic testing in the USA.

    abstract::Pulmonary arterial hypertension (PAH) is characterized by obstruction of pre-capillary pulmonary arteries, which leads to sustained elevation of pulmonary arterial pressure. Identifying those at risk through early interventions, such as genetic testing, may mitigate disease course. Current practice guidelines recommen...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1177/2045893217700156

    authors: Jacher JE,Martin LJ,Chung WK,Loyd JE,Nichols WC

    更新日期:2017-04-01 00:00:00

  • Pulmonary thromboembolism with computed tomography defined chronic thrombus is associated with higher mortality.

    abstract::With the advancement of computed tomography pulmonary angiography, differentiating between acute and chronic thrombus in pulmonary embolism has become more feasible. However, whether pulmonary embolism with chronic thrombus contributes to a higher mortality than pulmonary embolism with acute thrombus remains undetermi...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1177/2045894020905510

    authors: Chang HY,Chang WT,Chen PW,Lin CC,Hsu CH

    更新日期:2020-05-01 00:00:00

  • Non-invasive right ventricular load adaptability indices in patients with scleroderma-associated pulmonary arterial hypertension.

    abstract::Scleroderma-associated pulmonary arterial hypertension (SSc-PAH) is associated with worse outcome than idiopathic pulmonary arterial hypertension (IPAH), potentially due to worse right ventricular adaptation to load as suggested by pressure-volume loop analysis. The value of non-invasive load-adaptability metrics has ...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1177/2045894018788268

    authors: French S,Amsallem M,Ouazani N,Li S,Kudelko K,Zamanian RT,Haddad F,Chung L

    更新日期:2018-07-01 00:00:00

  • Serum soluble suppression of tumorigenicity-2 level associates with severity of pulmonary hypertension associated with uncorrected atrial septal defect.

    abstract::Uncorrected atrial septal defect undergoes right ventricle chronic volume overload which may lead to pulmonary hypertension and Eisenmenger Syndrome. The soluble suppression of tumorigenicity-2 is a left ventricle strain biomarker; however, its role in right ventricle strain is unclear. This study aimed to investigate...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1177/2045894020915832

    authors: Pratama RS,Hartopo AB,Anggrahini DW,Dewanto VC,Dinarti LK

    更新日期:2020-05-26 00:00:00

  • The genetics of pulmonary arterial hypertension in the post-BMPR2 era.

    abstract::Pulmonary arterial hypertension (PAH) is a rapidly progressive and fatal disease for which there is an ever-expanding body of genetic and related pathophysiological information on disease pathogenesis. The most common single culprit gene known is BMPR2, and animal models of the disease in several forms exist. There is...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.4103/2045-8932.87293

    authors: Fessel JP,Loyd JE,Austin ED

    更新日期:2011-07-01 00:00:00

  • Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension.

    abstract::Our aim is to assess the safety and potential efficacy of a novel treatment paradigm in pulmonary arterial hypertension (PAH), immunomodulation by blocking interleukin-6 (IL6) signaling with the IL6 receptor antagonist, tocilizumab. Inflammation and autoimmunity are established as important in PAH pathophysiology. One...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1177/2045893217735820

    authors: Hernández-Sánchez J,Harlow L,Church C,Gaine S,Knightbridge E,Bunclark K,Gor D,Bedding A,Morrell N,Corris P,Toshner M

    更新日期:2018-01-01 00:00:00

  • Low-grade albuminuria in pulmonary arterial hypertension.

    abstract::Low-grade albuminuria, determined by the urinary albumin to creatinine ratio, has been linked to systemic vascular dysfunction and is associated with cardiovascular mortality. Pulmonary arterial hypertension is related to mutations in the bone morphogenetic protein receptor type 2, pulmonary vascular dysfunction and i...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1177/2045894018824564

    authors: Nickel NP,de Jesus Perez VA,Zamanian RT,Fessel JP,Cogan JD,Hamid R,West JD,de Caestecker MP,Yang H,Austin ED

    更新日期:2019-04-01 00:00:00

  • S1P(4) receptor mediates S1P-induced vasoconstriction in normotensive and hypertensive rat lungs.

    abstract::This study aimed to identify receptors mediating sphingosine-1-phosphate (S1P)-induced vasoconstriction in the normotensive and chronic hypoxia-induced hypertensive rat pulmonary circulation. In isolated perfused lungs from normoxic rats, infusion of S1P caused a sustained vasoconstriction, which was not reduced by co...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.4103/2045-8932.87309

    authors: Ota H,Beutz MA,Ito M,Abe K,Oka M,McMurtry IF

    更新日期:2011-07-01 00:00:00

  • Gender, sex hormones and pulmonary hypertension.

    abstract::Most subtypes of pulmonary arterial hypertension (PAH) are characterized by a greater susceptibility to disease among females, although females with PAH appear to live longer after diagnosis. While this "estrogen paradoxȍ of enhanced female survival despite increased female susceptibility remains a mystery, recent pro...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章,评审

    doi:10.4103/2045-8932.114756

    authors: Austin ED,Lahm T,West J,Tofovic SP,Johansen AK,Maclean MR,Alzoubi A,Oka M

    更新日期:2013-04-01 00:00:00

  • Effects of tetrahydrobiopterin oral treatment in hypoxia-induced pulmonary hypertension in rat.

    abstract::Endothelial nitric oxide synthase (eNOS) plays a major role in maintaining pulmonary vascular homeostasis. Tetrahydrobiopterin (BH4), an essential cofactor that stabilizes the dimerization of eNOS and balances nitric oxide (NO) and superoxide production, may have therapeutic potential in pulmonary hypertension. In the...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1086/677361

    authors: Francis BN,Hale A,Channon KM,Wilkins MR,Zhao L

    更新日期:2014-09-01 00:00:00

  • Chemical and biological assessment of metal organic frameworks (MOFs) in pulmonary cells and in an acute in vivo model: relevance to pulmonary arterial hypertension therapy.

    abstract::Pulmonary arterial hypertension (PAH) is a progressive and debilitating condition. Despite promoting vasodilation, current drugs have a therapeutic window within which they are limited by systemic side effects. Nanomedicine uses nanoparticles to improve drug delivery and/or reduce side effects. We hypothesize that thi...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1177/2045893217710224

    authors: Mohamed NA,Davies RP,Lickiss PD,Ahmetaj-Shala B,Reed DM,Gashaw HH,Saleem H,Freeman GR,George PM,Wort SJ,Morales-Cano D,Barreira B,Tetley TD,Chester AH,Yacoub MH,Kirkby NS,Moreno L,Mitchell JA

    更新日期:2017-07-01 00:00:00

  • Trends in pediatric pulmonary hypertension-related hospitalizations in the United States from 2000-2009.

    abstract::There are few data on the epidemiology of pulmonary hypertension (PH)-related hospitalizations in children in the United States. Our aim was to determine hospital mortality, length of hospitalization, and hospital charges pertaining to PH-related hospitalizations and also the effects of codiagnoses and comorbidities. ...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1086/681226

    authors: Frank DB,Crystal MA,Morales DL,Gerald K,Hanna BD,Mallory GB Jr,Rossano JW

    更新日期:2015-06-01 00:00:00

  • Endothelial nitric oxide synthase genotype is associated with pulmonary hypertension severity in left heart failure patients.

    abstract::The biological mechanisms behind the development of pulmonary hypertension in the setting of left heart failure (HF-PH), including combined pre- and post-capillary pulmonary hypertension (Cpc-PH), remains unclear. This study aimed to use candidate polymorphisms in nitric oxide synthase (NOS) genes to explore the role ...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1177/2045894018773049

    authors: Duarte JD,Kansal M,Desai AA,Riden K,Arwood MJ,Yacob AA,Stamos TD,Cavallari LH,Zamanian RT,Shah SJ,Machado RF

    更新日期:2018-04-01 00:00:00

  • Understanding longitudinal biventricular structural and functional changes in a pulmonary hypertension Sugen-hypoxia rat model by cardiac magnetic resonance imaging.

    abstract::Cardiac magnetic resonance-derived ventricular variables are predictive of mortality in pulmonary arterial hypertension. Rodent models which emphasize ventricular function, allowing serial monitoring, are needed to identify pathophysiological features and novel therapies for pulmonary arterial hypertension. We investi...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1177/2045894019897513

    authors: Jayasekera G,Wilson KS,Buist H,Woodward R,Uckan A,Hughes C,Nilsen M,Church AC,Johnson MK,Gallagher L,Mullin J,MacLean MR,Holmes WM,Peacock AJ,Welsh DJ

    更新日期:2020-02-10 00:00:00

  • Riociguat use in sickle cell related chronic thromboembolic pulmonary hypertension: A case series.

    abstract::Adults with sickle cell disease can develop pulmonary hypertension from a multitude of etiologies. Classified as WHO Group 5, there are no therapies approved for the treatment of sickle cell disease-pulmonary hypertension. Thromboembolic disease is prevalent in sickle cell disease and can lead to pulmonary hypertensio...

    journal_title:Pulmonary circulation

    pub_type:

    doi:10.1177/2045894018791802

    authors: Weir NA,Conrey A,Lewis D,Mehari A

    更新日期:2018-10-01 00:00:00

  • Plasma acylcarnitines are associated with pulmonary hypertension.

    abstract::Quantifying metabolic derangements in pulmonary hypertension (PH) by plasma metabolomics could identify biomarkers useful for diagnosis and treatment. The objective of this paper is to test the hypotheses that circulating metabolites are differentially expressed in PH patients compared with controls and among differen...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1086/690554

    authors: Luo N,Craig D,Ilkayeva O,Muehlbauer M,Kraus WE,Newgard CB,Shah SH,Rajagopal S

    更新日期:2017-02-01 00:00:00

  • A non-selective endothelin receptor antagonist bosentan modulates kinetics of bone marrow-derived cells in ameliorating pulmonary hypertension in mice.

    abstract::The aim of this study was to investigate whether a dual endothelin receptor antagonist bosentan modulates the kinetics of bone marrow-derived stem cells in inhibiting the development of pulmonary hypertension. Bone marrow chimeric mice, transplanted with enhanced green fluorescent protein (eGFP)-positive bone marrow m...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1177/2045894020919355

    authors: Kato T,Mitani Y,Masuya M,Maruyama J,Sawada H,Ohashi H,Ikeyama Y,Otsuki S,Yodoya N,Shinohara T,Miyata E,Zhang E,Katayama N,Shimpo H,Maruyama K,Komada Y,Hirayama M

    更新日期:2020-05-14 00:00:00

  • The effects of genetic deletion of Macrophage migration inhibitory factor on the chronically hypoxic pulmonary circulation.

    abstract::While it is well established that the haemodynamic cause of hypoxic pulmonary hypertension is increased pulmonary vascular resistance, the molecular pathogenesis of the increased resistance remains incompletely understood. Macrophage migration inhibitory factor is a pleiotropic cytokine with endogenous tautomerase enz...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1177/2045894020941352

    authors: Li L,Xu M,Rowan SC,Howell K,Russell-Hallinan A,Donnelly SC,McLoughlin P,Baugh JA

    更新日期:2020-10-26 00:00:00

  • The unique heart sound signature of children with pulmonary artery hypertension.

    abstract::We hypothesized that vibrations created by the pulmonary circulation would create sound like the vocal cords during speech and that subjects with pulmonary artery hypertension (PAH) might have a unique sound signature. We recorded heart sounds at the cardiac apex and the second left intercostal space (2LICS), using a ...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1086/683694

    authors: Elgendi M,Bobhate P,Jain S,Guo L,Kumar S,Rutledge J,Coe Y,Zemp R,Schuurmans D,Adatia I

    更新日期:2015-12-01 00:00:00

  • An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension.

    abstract::Inhaled treprostinil (Tyvaso) has been shown to be a safe and effective addition to pulmonary arterial hypertension (PAH) oral therapies; however, the respiratory-related safety profile of inhaled treprostinil required further elucidation in the setting of routine clinical care. The objectives of this study were to ch...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1086/688059

    authors: Zamanian RT,Levine DJ,Bourge RC,De Souza SA,Rosenzweig EB,Alnuaimat H,Burger C,Mathai SC,Leedom N,DeAngelis K,Lim A,De Marco T

    更新日期:2016-09-01 00:00:00

  • Effects of dose and age on adverse events associated with tadalafil in the treatment of pulmonary arterial hypertension.

    abstract::There are limited data on the management of pulmonary arterial hypertension (PAH) in the elderly; therefore, this analysis compared the safety and efficacy of tadalafil between patients ≥65 and <65 years old. This was a post hoc analysis of the randomized, double-blind, placebo-controlled phase 3 Pulmonary Arterial Hy...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1086/674901

    authors: Berman-Rosenzweig E,Arneson C,Klinger JR

    更新日期:2014-03-01 00:00:00

  • Atrial arrhythmias in chronic lung disease-associated pulmonary hypertension.

    abstract::Atrial arrhythmias are common during episodes of acute respiratory failure in patients with chronic lung disease-associated pulmonary hypertension. Expert opinion suggests that management of atrial arrhythmias in patients with pulmonary hypertension should aim to restore sinus rhythm. This is clinically challenging in...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章,评审

    doi:10.1177/2045894020910685

    authors: Vahdatpour CA,Luebbert JJ,Palevsky HI

    更新日期:2020-03-09 00:00:00

  • Pulmonary capillary hemangiomatosis: the role of invasive cardiopulmonary exercise testing.

    abstract::Pulmonary capillary hemangiomatosis (PCH) is a rare form of pulmonary arterial hypertension (PAH) characterized by pulmonary capillary proliferation and pseudoinvasion of collagenous septal structures. PCH is often accompanied by veno-occlusive changes and pulmonary hypertensive arterial remodeling. The clinical and p...

    journal_title:Pulmonary circulation

    pub_type:

    doi:10.1086/682227

    authors: DuBrock HM,Kradin RL,Rodriguez-Lopez JM,Channick RN

    更新日期:2015-09-01 00:00:00

  • Dysregulation of ubiquitin-proteasome pathway and apolipoprotein A metabolism in sickle cell disease-related pulmonary arterial hypertension.

    abstract::Pulmonary arterial hypertension (PAH) is a major complication of sickle cell disease (SCD). Low levels of apolipoprotein A1 (Apo-A1) have been implicated in the development of PAH in SCD. We speculate that lower levels of Apo-A1 are related to dysregulation of the ubiquitin-proteasome pathway (UPP). Of 36 recruited pa...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1086/674763

    authors: Anjum F,Lazar J,Soh J,Albitar M,Gowda S,Hussain MM,Wadgaonkar R

    更新日期:2013-12-01 00:00:00

  • Occult catheter rupture causing episodic symptoms in a patient treated with epoprostenol.

    abstract::Infection, thrombosis, and catheter dislodgment are well-recognized potential complications of chronic intravenous prostanoid therapy for pulmonary arterial hypertension. As long-term outcomes of pulmonary hypertension patients improve, novel adverse events are likely to arise. We describe the sudden development of un...

    journal_title:Pulmonary circulation

    pub_type:

    doi:10.1177/2045893217748054

    authors: LeVarge BL,Law AC,Murphy B

    更新日期:2018-01-01 00:00:00

  • BMPR2 mutations and endothelial dysfunction in pulmonary arterial hypertension (2017 Grover Conference Series).

    abstract::Despite the discovery more than 15 years ago that patients with hereditary pulmonary arterial hypertension (HPAH) inherit BMP type 2 receptor ( BMPR2) mutations, it is still unclear how these mutations cause disease. In part, this is attributable to the rarity of HPAH and difficulty obtaining tissue samples from patie...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1177/2045894018765840

    authors: Frump A,Prewitt A,de Caestecker MP

    更新日期:2018-04-01 00:00:00